Tryptamine Therapeutics Ltd
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 … Read more
Tryptamine Therapeutics Ltd (TYP) - Total Assets
Latest total assets as of December 2023: AU$3.08 Million AUD
Based on the latest financial reports, Tryptamine Therapeutics Ltd (TYP) holds total assets worth AU$3.08 Million AUD as of December 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tryptamine Therapeutics Ltd - Total Assets Trend (2015–2023)
This chart illustrates how Tryptamine Therapeutics Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Tryptamine Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (June 2023)
Tryptamine Therapeutics Ltd's total assets of AU$3.08 Million consist of 78.0% current assets and 22.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 27.9% |
| Accounts Receivable | AU$66.06K | 1.1% |
| Inventory | AU$159.95K | 2.7% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$284.38K | 4.8% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2015–2023)
This chart illustrates how Tryptamine Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tryptamine Therapeutics Ltd's current assets represent 78.0% of total assets in 2023, a decrease from 100.0% in 2015.
- Cash Position: Cash and equivalents constituted 27.9% of total assets in 2023, up from 0.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 4.8% of total assets.
Tryptamine Therapeutics Ltd Competitors by Total Assets
Key competitors of Tryptamine Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Tryptamine Therapeutics Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Tryptamine Therapeutics Ltd generates 0.11x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Tryptamine Therapeutics Ltd is currently not profitable relative to its asset base.
Tryptamine Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.82 | 1.62 | 34.75 |
| Quick Ratio | 7.82 | 1.62 | 34.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$2.33 Million | AU$ 1.67 Million | AU$ 6.08 Million |
Tryptamine Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Tryptamine Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.19 |
| Latest Market Cap to Assets Ratio | 3.37 |
| Asset Growth Rate (YoY) | -56.8% |
| Total Assets | AU$5.88 Million |
| Market Capitalization | $19.83 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Tryptamine Therapeutics Ltd's assets at a significant premium ( 3.37x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Tryptamine Therapeutics Ltd's assets decreased by 56.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Tryptamine Therapeutics Ltd (2015–2023)
The table below shows the annual total assets of Tryptamine Therapeutics Ltd from 2015 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-06-30 | AU$5.88 Million | -56.80% |
| 2022-06-30 | AU$13.61 Million | -36.55% |
| 2021-06-30 | AU$21.46 Million | +227.96% |
| 2020-06-30 | AU$6.54 Million | +21.14% |
| 2019-06-30 | AU$5.40 Million | -24.93% |
| 2018-06-30 | AU$7.19 Million | +14388418.00% |
| 2015-06-30 | AU$50.00 | -- |